Onconetix Corp - ONCO Net earnings per share for the last four quarters

Onconetix Inc (ONCO) - corporate logo

Onconetix, Inc. (ONCO) is implementing advanced diagnostic and therapeutic methods for men's health while minimizing side effects. The business is currently restructuring its client base, leveraging the distribution of specialized products. Revenues are based on the supply of targeted prostate treatment agents to clinics. The year-over-year EPS (TTM) history on the GURU.Markets chart demonstrates profit dynamics, where the value of 99.60 expresses the metric level.

ONCO Onconetix Corp: Earnings per share for the last twelve months in the range 11/23/2025 - 11/18/2026

onconetix.gcs-web.com - analytical breakdowns and key metrics (ONCO)

- market price and analyst price targets:
Initial company analysis:ONCO, Onconetix Inc
Finished products of Onconetix, Inc.

This indicator measures the annual dynamics of net income per share, smoothing quarterly volatility via a twelve-month rolling window. Analyzing the 12-month YoY net income per share change allows for an assessment of the business's actual operational efficiency. The metric discounts the impact of costs on final shareholder returns. For Onconetix, Inc. (ONCO), this is critical when adapting assets following a merger. Investors use this chart to monitor pipeline commercialization and the stabilization of device sales.

Competitor analysis

A - Net earnings per share (EPS TTM)|Quest Corp (DGX) - Earnings per share for the last twelve months|ILMN - Net earnings per share for the last four quarters|Earnings per share for the last twelve months exactsciences.com|revvity.com (RVTY) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) BIO|Net earnings per share (EPS TTM) Anbio Biotechnology Ltd (NNNN)|Sotera Health - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) QuidelOrtho Corp QDEL|OPK - Earnings per share for the last twelve months|Earnings per share for the trailing year CDNA (caredx.com)|MRVI: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Fulgent Genetics FLGT|LAB (Standard BioTools Inc) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Cytek Biosciences, Inc.|Earnings per share for the last twelve months OraSure Technologies (OSUR)|XGN (Exagen) - Earnings per share for the trailing year|Earnings per share for the last twelve months MDxHealth MDXH|LUCD: Earnings per share for the last 12 months|PRE - Earnings per share for the last twelve months|Earnings per share for the trailing year IMDX (Insight Molecular Diagnostics Inc)|TRIB: Net earnings per share (EPS TTM)|prophaselabs.com - Earnings per share for the trailing year|Net earnings per share for the last 12 months AIMD|Co-Diagnostics Corp (CODX) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months HSCS (Heart Test Laboratories Inc.)|Net earnings per share for the last four quarters Biomerica Inc|Earnings per share for the last twelve months cardiodiagnosticsinc.com CDIO|viraxbiolabs.com - Earnings per share for the last twelve months|BJDX - Earnings per share for the last twelve months|Earnings per share for the trailing year AWH (Aspira Women's Health Inc.)|AXDX: Net earnings per share (EPS TTM)|CNTG - Net earnings per share for the last four quarters|ENZ (enzo.com) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months FRES|Earnings per share for the last twelve months Genetic Technologies (GENE)|Net earnings per share for the last four quarters 23andMe Holding Co|Net earnings per share (EPS TTM) PMD (Psychemedics)